Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
文献类型：期刊论文
| 作者 | Liu, Jiaqi2; Gu, Jianying2; Feng, Zihao2; Yang, Yanhong3; Zhu, Ningwen1; Lu, Weiyue4; Qi, Fazhi2 |
| 刊名 | JOURNAL OF TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2016-01-08 |
| 卷号 | 14 |
| 关键词 | Melanoma HDAC inhibitors HDAC5 HDAC6 Proliferation Metastasis |
| ISSN号 | 1479-5876 |
| DOI | 10.1186/s12967-015-0753-0 |
| 文献子类 | Article |
| 英文摘要 | Background: Histone deacetylase (HDAC) inhibitors are widely used in clinical investigation as novel drug targets. For example, panobinostat and vorinostat have been used to treat patients with melanoma. However, HDAC inhibitors are small-molecule compounds without a specific target, and their mechanism of action is unclear. Therefore, it is necessary to investigate which HDACs are required for the proliferation and metastasis of melanoma cells. Methods: We used overexpression and knocking down lentivirus to clarify the influence of HDAC5 and HDAC6 in melanoma development. Also, we introduced stable HDAC5 or HDAC6 knockdown cells into null mice and found that the knockdown cells were unable to form solid tumors. Finally, we tested HDAC5 and HDAC6 expression and sublocation in clinical melanoma tissues and tumor adjacent tissues. Results: In this study, and found that HDAC5 and HDAC6 were highly expressed in melanoma cells but exhibited low expression levels in normal skin cells. Furthermore, we knocked down HDAC5 or HDAC6 in A375 cells and demonstrated that both HDAC5 and HDAC6 contributed to the proliferation and metastasis of melanoma cells. Conclusions: This study demonstrated both HDAC5 and HDAC6 were required for melanoma cell proliferation and metastasis through different signaling pathways. |
| WOS关键词 | HISTONE DEACETYLASE INHIBITOR ; SOLID TUMORS ; DEPENDENT ACTIVATION ; PHASE-I ; ACETYLATION ; CANCER ; EXPRESSION ; APOPTOSIS ; LYMPHOMA ; BUTYRATE |
| 资助项目 | Major State Basic Research Development Program of China (973 Program)[2013CB932502] ; National High Technology Research and Development Program of China (863 Program)[2014AA020705] |
| WOS研究方向 | Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000368393100001 |
| 出版者 | BIOMED CENTRAL LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276179]  |
| 专题 | 新药研究国家重点实验室 中科院受体结构与功能重点实验室 |
| 通讯作者 | Qi, Fazhi |
| 作者单位 | 1.Fudan Univ, Huashan Hosp, Shanghai 200040, Peoples R China; 2.Fudan Univ, Zhongshan Hosp, Dept Plast Surg, Shanghai 200032, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 4.Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Jiaqi,Gu, Jianying,Feng, Zihao,et al. Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells[J]. JOURNAL OF TRANSLATIONAL MEDICINE,2016,14. |
| APA | Liu, Jiaqi.,Gu, Jianying.,Feng, Zihao.,Yang, Yanhong.,Zhu, Ningwen.,...&Qi, Fazhi.(2016).Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.JOURNAL OF TRANSLATIONAL MEDICINE,14. |
| MLA | Liu, Jiaqi,et al."Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells".JOURNAL OF TRANSLATIONAL MEDICINE 14(2016). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。